Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) announced it had filed its new provisional patent application with the United States Patent and Trademark Office that extends its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs.
In a statement, the Toronto-based company said that the most recent application covers a “comprehensive range” of next generation drug candidates, as well as their related chemical process synthesis, composition of matter and therapeutic uses.
READ: Mindset Pharma advances psychedelic drug candidates' development as its patent applications are published
“The second patent application for our novel drug candidates incorporates new side-chain restricted analog designs - working from the progress of our first application - and broadens the strength of our patent estate,” James Lanthier, CEO of Mindset, told shareholders.
“Our DMT/5-MeO-DMT analogs have shown a range of duration and pharmacological diversity in preclinical modeling, with the potential to offer a more convenient and individualized administration for clinic-based therapies.”
Family 4 compounds are DMT and 5-MeO-DMT inspired drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings, according to the psychedelics firm.
Mindset has conducted in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas